Text this: Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

  _  _    __   __    _  __     ___      ____    
 | \| ||  \ \\/ //  | |/ //   / _ \\   |  _ \\  
 |  ' ||   \ ` //   | ' //   / //\ \\  | |_| || 
 | .  ||    | ||    | . \\  |  ___  || | .  //  
 |_|\_||    |_||    |_|\_\\ |_||  |_|| |_|\_\\  
 `-` -`     `-`'    `-` --` `-`   `-`  `-` --`